Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: Results of National Cancer Institute/Children's Cancer Group Trials CCG-191P, CCG-134P and CCG-144P

Leukemia and Lymphoma

Volumn 47, Issue 12, 2006, Pages 2488-2504

  Nathan, Paul C ^a   Whitcomb, Trish ^a   Wolters, Pamela L ^a,c   Steinberg, Seth M ^b   Balis, Frank M ^a   Brouwers, Pim ^a   Hunsberger, Sally ^b   Feusner, James ^e   Sather, Harland ^f   Miser, James ^g   Odom, Lorrie F ^h   Poplack, David ^a   Reaman, Gregory ⁱ   Bleyer, Archie ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Medical Illness Counseling Center   (United States)

^d Division of Pulmonology   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

^f CHILDREN S ONCOLOGY GROUP   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h CHILDREN S HOSPITAL   (United States)

ⁱ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute; Child; Intelligence tests; Leukemia; Lymphocytic; Methotrexate

Indexed keywords

AMINOTRANSFERASE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COGNITION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; INFANT; INTELLIGENCE QUOTIENT; KIDNEY FAILURE; LEUKEMIA RELAPSE; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL CAPACITY; MENTAL TEST; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS; SIDE EFFECT;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COGNITION; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; PILOT PROJECTS; RISK; TREATMENT OUTCOME;

EID: 33845584082     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600942769     Document Type: Article

References (50)

1. Ries, L and Eisner, M and Kosary, C and Hankey, B and Miller, B and Clegg, L and (2003) SEER Cancer Statistics Review, 1975 - 2000. Bethesda MD: National Cancer Institute.
2. Jankovic, M and Brouwers, P and Valsecchi, M and Van Veldhuizen, A and Huisman, J and Kamphuis, R and (1994) Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer Lancet, 344, pp. 224-227.
3. Howard, S and Pui, C. (2002) Endocrine complications in pediatric patients with acute lymphoblastic leukemia Blood Rev, 16, pp. 225-243.
4. Relling, M and Rubnitz, J and Rivera, G and Boyett, J and Hancock, M and Felix, C and (1999) High incidence of secondary brain tumours after radiotherapy and antimetabolites Lancet, 354, pp. 34-39.
5. Pui, C and Cheng, C and Leung, W and Rai, S and Rivera, G and Sandlund, J and (2003) Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia N Engl J Med, 349, pp. 640-649.
6. Perel, Y and Leverger, G and Carrere, A and Caudry, M and Garabedian, E and Ansoborlo, S and (1998) Second thyroid neoplasms after prophylactic cranial irradiation for acute lymphoblastic leukemia Am J Hematol, 59, pp. 91-94.
7. Nesbit, M, Jr and Sather, H and Robison, L and Ortega, J and Littman, P and D'Angio, G and (1981) Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukaemia: comparison of 1800 rad and 2400 rad. A report for Children's Cancer Study Group Lancet, 1, pp. 461-466.
8. Bleyer, W and Poplack, D. (1985) Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries Semin Oncol, 12, pp. 131-148.
9. Balis, F and Blaney, S and McCully, C and Bacher, J and Murphy, R and Poplack, D. (2000) Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration Cancer Chemother Pharmacol, 45, pp. 259-264.
10. Shapiro, W and Young, D and Mehta, B. (1975) Methotrexate: Distribution in cerebrosopinal fluid after intravenous, ventricular and lumbar injections N Engl J Med, 293, pp. 161-166.
11. Hryniuk, W and Bertino, J. (1969) Treatment of leukemia with large doses of methotrexate and folinic acid: Clincial-biochemical correlates J Clin Invest, 48, pp. 2140-2155.
12. Bleyer, W and Poplack, D.(1978) Clinical studies on the central-nervous-system pharmacology of methotrexate. In Clinical Pharmacology of Anti-Neoplastic Drugs. (pp. 115-131). Amsterdam: Elsevier/North Holland Biomedical.
13. Morse, M and Savitch, J and Balis, F and Miser, J and Feusner, J and Reaman, G and (1985) Altered central-nervous-system pharmacology of methotrexate in childhood leukemia: Another sign of meningeal relapse J Clin Oncol, 3, pp. 19-24.
14. Balis, F and Savitch, J and Bleyer, W and Reaman, G and Poplack, D. (1985) Remission induction of meningeal leukemia with high-dose intravenous methotrexate J Clin Oncol, 3, pp. 485-489.
15. McCarthy, D.(1972) McCarthy Scales of Children's Abilities. San Antonio TX: Psychological Corporation.
16. Wechsler, D.(1974) Wechsler Intelligence Scale for Children - Revised. San Antonio TX: Psychological Corporation.
17. Wechsler, D.(1955) Wechsler Adult Intelligence Scale. New York NY: The Psychological Corporatoin.
18. Wechsler, D.(1981) Wechsler Adult Intelligence Scale - Revised. San Antonio TX: Psychological Corporation.
19. Kaplan, E and Meier, P. (1958) Nonparametric estimation from incomplete observations J Am Stat Assoc, 53, pp. 457-481.
20. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep, 50, pp. 103.
21. Laird, N and Ware, J. (1982) Random-effects models for longitudinal data Biometrics, 38, pp. 963-974.
22. Smith, M and Arthur, D and Camitta, B and Carroll, A and Crist, W and Gaynon, P and (1996) Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia J Clin Oncol, 14, pp. 18-24.
23. Nachman, J and Sather, H and Cherlow, J and Sensel, M and Gaynon, P and Lukens, J and (1998) Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group J Clin Oncol, 16, pp. 920-930.
24. Hill, F and Richards, S and Hann, I and Gibson, B and Lilleyman, J and Kinsey, S and (2004) Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukemia: Results of a risk-stratified randomized central nervous system treatment trial MRC UKALL XI Br J Haematol, 124, pp. 33-46.
25. Gaynon, P and Trigg, M and Heerema, N and Sensel, M and Sather, H and Hammond, G and (2000) Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983 -1995 Leukemia, 14, pp. 2223-2233.
26. Clarke, M and Gaynon, P and Hann, I and Harrison, G and Masera, G and Peto, R and (2003) CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group Overview of 43 randomized trials J Clin Oncol, 21, pp. 1798-1809.
27. Moe, P and Holen, A and Nygaard, R and Glomstein, A and Madsen, B and Hellebostad, M and (2003) Methotrexate infusions as central nervous system prophylaxis in children with acute lymphoblastic leukemia: The Norwegian experience Pediatr Hematol Oncol, 20, pp. 187-200.
28. Camitta, B and Mahoney, D and Leventhal, B and Lauer, S and Shuster, J and Adair, S and (1994) Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study J Clin Oncol, 12, pp. 1383-1389.
29. Kamps, W and Bokkerink, J and Hahlen, K and Hermans, J and Riehm, H and Gadner, H and (1999) Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988 - 1991) Blood 94, pp. 1226-1236.
30. Silverman, L and Gelber, R and Dalton, V and Asselin, B and Barr, R and Clavell, L and (2001) Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01 Blood, 97, pp. 1211-1218.
31. Pui, C and Sandlund, J and Pei, D and Campana, D and Rivera, G and Ribeiro, R and (2004) Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital Blood, 104, pp. 2690-2696.
32. Pui, C and Evans, W. (2006) Treatment of acute lymphoblastic leukemia N Engl J Med, 354, pp. 166-178.
33. Burger, B and Zimmermann, M and Mann, G and Kuhl, J and Loning, L and Riehm, H and (2003) Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture J Clin Oncol, 21, pp. 184-188.
34. Moore, B, III. (2005) Neurocognitive outcomes in survivors of childhood cancer J Pediatr Psychol, 30, pp. 51-63.
35. Copeland, D and Fletcher, J and Pfefferbaum-Levine, B and Jaffe, N and Ried, H and Maor, M. (1985) Neuropsychological sequelae of childhood cancer in long-term survivors Pediatrics, 75, pp. 745-753.
36. Mulhern, R and Fairclough, D and Ochs, J. (1991) A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation J Clin Oncol, 9, pp. 1348-1356.
37. Rowland, J and Glidewell, O and Sibley, R and Holland, J and Tull, R and Berman, A and (1984) Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia J Clin Oncol, 2, pp. 1327-1335.
38. Trautman, P and Erickson, C and Shaffer, D and O'Connor, P and Sitarz, A and Correra, A and (1988) IS. Prediction of intellectual deficits in children with acute lymphoblastic leukemia J Dev Behav Pediatr, 9, pp. 122-128.
39. Brown, R and Madan-Swain, A and Pais, R and Lambert, R and Baldwin, K and Casey, R and (1992) Cognitive status of children treated with central nervous system prophylactic chemotherapy for acute lymphocytic leukemia Arch Clin Neuropsychol, 7, pp. 481-497.
40. Brown, R and Sawyer, M and Antoniou, G and Rice, M. (1999) Longitudinal follow-up of the intellectual and academic functioning of children receiving central nervous system-prophylactic chemotherapy for leukemia: a four-year final report Dev Behav Pediatr, 20, pp. 373-377.
41. Reaman, G and Sposto, R and Sensel, M and Lange, B and Feusner, J and Heerema, N and (1999) Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group J Clin Oncol, 17, pp. 445-455.
42. Evans, W and Pui, C and Relling, M.(1999) Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. In Drug Resistance in Leukemia and Lymphoma III. (pp. 537-541). New York NY: Kluwer Academic/Plenum Publishers.
43. Evans, W and Crom, W and Abromowitch, M and Dodge, R and Look, A and Bowman, W and (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect N Engl J Med, 314, pp. 471-477.
44. Camitta, B and Leventhal, B and Lauer, S and Shuster, J and Adair, S and Casper, J and (1989) Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study J Clin Oncol, 7, pp. 1539-1544.
45. Evans, W and Schell, M and Pui, C. (1990) MTX clearance is more important for intermediate-risk ALL J Clin Oncol, 8, pp. 1115-1119.
46. Keefe, D and Capizzi, R and Rudnick, S. (1982) Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: Relationship of dose and duration of exposure to tumor cell viability Cancer Res, 42, pp. 1641-1645.
47. Schrappe, M and Reiter, A and Henze, G and Niemeyer, C and Bode, U and Kuhl, J and (1998) Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials Klinische Padiatrie, 210, pp. 192-199.
48. Littman, P and Coccia, P and Bleyer, W and Lukens, J and Siegel, S and Miller, D and (1987) Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL) Int J Radiat Oncol Biol Phys, 13, pp. 1443-1449.
49. Conter, V and Arico, M and Valsecchi, M and Rizzari, C and Testi, A and Messina, C and (1995) Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica J Clin Oncol, 13, pp. 2497-2502.
50. Tubergen, D and Gilchrist, G and O'Brien, R and Coccia, P and Sather, H and Waskerwitz, M and (1993) Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group report J Clin Oncol, 11, pp. 520-526.